NIH Partners with 9 CLSA Member Biopharma Companies to Accelerate Cancer Therapy Innovation

Oct. 21, 2017

On Oct. 12, the National Institutes of Health (NIH) announced a new partnership with 11 biopharmaceutical companies aimed at accelerating innovation in new cancer immunotherapy therapies.  We are very proud that nine CLSA member companies are participating in the initiative, which is demonstrative of the expertise and commitment of California innovators in driving groundbreaking research efforts that will lead to future treatments and cures.

The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $215 million, that supports the Cancer Moonshot goal of bringing immunotherapy success for more cancers to more patients.

PACT partners include CLSA members AbbVie; Amgen; Boehringer Ingelheim Pharma GmbH & Co. KG; Bristol-Myers Squibb; Celgene Corporation; Genentech, a member of the Roche Group; Gilead Sciences; Janssen Pharmaceutical Companies of Johnson & Johnson; and Pfizer, Inc.; as well as GlaxoSmithKline plc; and Novartis Institutes for Biomedical Research.

Additionally, NIH’s National Cancer Institute (NCI) recently awarded cooperative agreements to support four Cancer Immune Monitoring and Analysis Centers (CIMACs) and a Cancer Immunologic Data Commons (CIDC) with a total of $53.6 million in funding over five years. The four CIMACs and one CIDC will form a network of laboratory centers that will support both adult and pediatric immunotherapy trials. Researchers at the CIMACs will perform deep tumor and immune profiling. The resulting data will be collected in the CIDC database for exploration of biomarkers of immune response. This network will also provide a foundation for the core laboratory, assay development and database functions required by PACT. Notably, Stanford Cancer Institute (Palo Alto, CA), is among the cooperative agreement awardees. (Stanford University is a member of CLSA).

Congratulations to all participants in launching this landmark initiative! Click here to learn more about the announcement. Questions? Please contact Adam Lotspike, CLSA’s Associate Director, Federal Government Relations (